Breakthrough COVID-19 after tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases
Description
CONCLUSION: We found that SARD patients had frequent breakthrough COVID-19, but the proportion experiencing severe COVID-19 was low. DMARD type, including CD20 inhibitors, did not significantly affect risk of breakthrough COVID-19. Evidence of prior
